Back to Acceleration Radar
LNTHLantheus Holdings Inc
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · Mid
$99.80−0.30%
As of 23 Oct 2026Mkt cap $6.6B
Stage 13
WAIT
Fundamentals
45.2/75
Technical
7.2/15
Independent
52.4/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- +0.1%
- 3M
- −7.6%
- 6M
- +18.3%
- 1Y
- +74.7%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 24.2xHist median 21.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 16.8x
- FCF yield
- 6.0%
Quality
- ROIC
- 22.7%
- Operating margin
- 28.1%
- FCF margin
- 25.3%
- Current ratio
- 2.7x
Growth
- Revenue growth
- +0.5%Latest FY YoY
- Revenue CAGR
- +38.0%
- EPS CAGR
- −14.4%
- FCF CAGR
- +64.0%
Capital
- Share-count trend
- −1.3%3Y annualised
- Net debt
- $210M0.5x OCF
Annual trend
- CAGR 2021–2025
- +38.0%
- Latest · 2025
- $2B
- YoY
- +0.5%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded